From June 26 to 29, Tianjin Pharmaceutical Group showcased its family of skin medication products at the 30th Annual Meeting of the Chinese Medical Association on Dermatology and Venereology (CSD 2025).

The CSD Annual Meeting is the largest annual academic event for dermatologists in my country. During the conference, Tianjin Pharmaceutical Group showcased its top-tier topical preparations, including hydrocortisone butyrate cream (Eucerin), clopidogrel-hydroxyquine cream (Keailin), compound cod liver oil and zinc oxide ointment (Fuliping), halometasone cream (Youlening), and diflubenzuron valerate cream, as well as core oral hormone products such as prednisone tablets (Meilesong) and triamcinolone tablets (Aceton). The company's comprehensive product portfolio demonstrated its extensive product line. The company also meticulously prepared the latest clinical guidelines and literature for its core products, providing precise and attentive service to its clients. The company's specially designed booth attracted nearly a thousand clinical experts and doctors who stopped for consultations and discussions.

During the event, the company presented its "Keailin" poster results, presented at the 2025 International Congress of Dermatology (ICD), through expert interviews. This allowed attendees to gain a more intuitive and in-depth understanding of the product's latest research progress and clinical application value. As a proprietary product of Tianjin Pharmaceutical Group, Keailin has attracted significant attention. This poster presentation further demonstrates its outstanding efficacy and safety in the field of skin treatment, providing clinicians with more treatment ideas and methods.

Article by: Health Technology Company